Stock Research for JNJ

Featured Broker: Ally Invest

Get the due diligence for another stock.


JNJ Stock Chart & Research Data

The JNJ chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the JNJ chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


JNJ Due diligence Resources & Stock Charts

The JNJ stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View JNJ Detailed Price Forecast - CNN Money CNN View JNJ Detailed Summary - Google Finance
Yahoo View JNJ Detailed Summary - Yahoo! Finance Zacks View JNJ Stock Research & Analysis -

Stock Analysis

TradeIdeas View JNJ Trends & Analysis - Trade-Ideas Barrons View JNJ Major Holders - Barrons
NASDAQ View JNJ Call Transcripts - NASDAQ Seeking View JNJ Breaking News & Analysis - Seeking Alpha
Spotlight View JNJ Annual Report - OTC Report View JNJ OTC Short Report -
TradeKing View JNJ Fundamentals - TradeKing Charts View JNJ SEC Filings - Bar Chart
WSJ View Historical Prices for JNJ - The WSJ Morningstar View Performance/Total Return for JNJ - Morningstar
MarketWatch View the Analyst Estimates for JNJ - MarketWatch CNBC View the Earnings History for JNJ - CNBC
StockMarketWatch View the JNJ Earnings - StockMarketWatch MacroAxis View JNJ Buy or Sell Recommendations - MacroAxis
Bullish View the JNJ Bullish Patterns - American Bulls Short Pains View JNJ Short Pain Metrics -

Social Media Mentions

StockTwits View JNJ Stock Mentions - StockTwits PennyStocks View JNJ Stock Mentions - PennyStockTweets
Twitter View JNJ Stock Mentions - Twitter Invest Hub View JNJ Investment Forum News - Investor Hub
Yahoo View JNJ Stock Mentions - Yahoo! Message Board Seeking Alpha View JNJ Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for JNJ - Insider Cow View Insider Transactions for JNJ - Insider Cow
CNBC View JNJ Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for JNJ - OTC Markets
Yahoo View Insider Transactions for JNJ - Yahoo! Finance NASDAQ View Institutional Holdings for JNJ - NASDAQ

Stock Charts

FinViz View JNJ Stock Insight & Charts - StockCharts View JNJ Investment Charts -
BarChart View JNJ Stock Overview & Charts - BarChart Trading View View JNJ User Generated Charts - Trading View

Latest Financial News for JNJ

British businesses embrace profits with a purpose
Posted on Sunday April 22, 2018

Like many combat veterans, Steve Hammond struggled for years after returning to civilian life, battling physical injuries that made it difficult to find a job and left him contemplating suicide. Now the 61-year-old father of two is thriving as a team leader with Britain's Bravest Manufacturing Company (BBMC), one of a growing number of socially-minded companies providing jobs for people marginalised from the traditional workforce. "It gives people with a disability or mental health issues a purpose in life," Hammond, who was wounded in the Falklands War, told the Thomson Reuters Foundation.

3 Things You Should Know About Today's Top Entrepreneurs
Posted on Sunday April 22, 2018

A new wave of innovation will change several of America's most established industries. Here are three important takeaways for investors.

Johnson & Johnson's First-Quarter 2018 Earnings Review
Posted on Sunday April 22, 2018

We discuss the pros and cons for J&J’s latest quarterly results, plus Alkermes gets a do-over and Celldex flops.

[$$] Square, eBay, and the Future of Money
Posted on Friday April 20, 2018

Earnings per share were higher despite a higher tax rate and a lower contribution from other income. What we didn’t like about the first quarter: 1) the pharma mix was not optimal, as key drugs Actelion, Darzalex, and Xarelto all missed our estimate. U.S. Remicade was down 16% Y/Y, in line with our estimate, but we were hoping for better.

Enter a stock symbol to view the stock details.